Clinical significance of serum TPOAb monitoring during 131I treatment in patients with Graves' disease
10.3760/cma.j.issn.1673-4130.2009.10.010
- VernacularTitle:Graves甲亢131I治疗中动态监测血清TPOAb的临床价值
- Author:
Yanghang LI
;
Feng CHEN
;
Liu LIU
- Publication Type:Journal Article
- Keywords:
Graves' disease;
And-thyroid peroxidase antibody(TPOAb);
131I treatment;
Hypothyroidism
- From:
International Journal of Laboratory Medicine
2009;30(10):960-962
- CountryChina
- Language:Chinese
-
Abstract:
Objective The investigate the clinical significance of serum anti-thyroid peroxidase antibody(TPOAb)monitoring in therapeutic effect judgment and prognosis evaluation during 131I treatment in patients with Graves disease.Methods A total of 112 patients with Graves disease(hyperthyroidism group)and 50 healthy controls(healthy control group)were enrolled in the investigation.Serum concentration of TPOAb was measured with chemiluminescent immunoassay(CLIA)in healthy control group and hyperthyroidism group(at time points of 0,3,6,12 and 24 months after 131I treatment,i.e.T0,T3,T6,T12 and T24).Variance analysis and t test were adopted.Results The mean level of TPOAb was significantly higher in patients with Graves' disease before 131I treatment than that in healthy controls(P＜0.01).In hypenthyroidism group,serum concentration of TPOAb was evidently higher at T3[(108.94±70.15)IU/mL]than T0[(81.95±47.64)IU/mL](P＜0.01);TPOAb level began to decline at T6[(42.78±28.68)IU/mL],but still higher than that of healthy control group;while where was no statistical difference in TPOAb level between hyperthyroidism group at T24[(7.89±4.01)IU/mL]and healthy control group(F＞0.05).Conclusion Serum level of TPOAb before treatment may be used as an auxiliary indicator of 131I dosage.Posttreatment TPOAb level monitoring contributes to therapeutic effect evaluation,follow-up visit and immunorcaction state understanding.
